In keeping with this epigenetic reprograming of cancer cells, EZH2 inhibition was found to be associated with M1 TAMs reprogramming, increased recruitment of activated CD8+ T cells and enhanced response to PD-1 blockade in vivo [129]. Here, CD8A is linked to cancer.